Research
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy
and Safety of Oral Brepocitinib in Adults with Dermatomyositis. NCT05437263
- A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Phase
3 Trial to Evaluate the Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-Care
Therapy in Participants with Active Lupus Nephritis (SIRIUS-LN). NCT05126277
- A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate
Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-Care Therapy
In Patients \with Systemic Lupus Erythematosus (SIRIUS-SLE 2). NCT05624749
- The COvid19 VaccinE Response and Co-Administration in Rheumatology patients (COVER-CoAd).
NCT05543642
- A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study
to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with
Moderately to Severely Active Systemic Lupus Erythematosus. NCT06617325
- A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multicenter Study to
Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants with Diffuse
Cutaneous Systemic Sclerosis. NCT06470048
- A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and
Safety of Belimumab Administered Subcutaneously in Adult Participants with Early Systemic
Lupus Erythematosus. NCT06411249
- A Phase 2a, Open Label, Multicenter Study to Assess the Safety, Tolerability, And
Efficacy of Subcutaneously Administered Blinatumomab in Subjects with Active and Refractory
Systemic Lupus Erythematosus with Nephritis (Subprotocol B). NCT06570798
- A Phase 2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and
Efficacy Of Subcutaneously Administered Blinatumomab in Participants with Active Refractory
Rheumatoid Arthritis (Subprotocol C). NCT06570798
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy
and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus
(SLE) (POETYK SLE-2). NCT05620407
- A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group
Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants
With Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity.
NCT06979531
- A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate
the Efficacy and Safety of PF-06823859 in Participants with Active Idiopathic Inflammatory
Myopathies (Including Participants with Active Dermatomyositis or Polymyositis.)
NCT05895786
- A Randomized, Double-Blind, Placebo-Controlled Extension Study to Assess the Long-Term
Safety and Tolerability of Ianalumab in Patients with Systemic Lupus Erythematosus
(SIRIUS-SLE Extension). NCT06133972
- A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy
and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis Who
Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors. NCT07137598
- A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants with Systemic Lupus Erythematosus. NCT04976322